| 1 |
33000474 | Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report. | 2021 Mar |
1 |
| 2 |
33945921 | Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion. | 2021 |
1 |
| 3 |
34319660 | A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib. | 2021 Sep |
1 |
| 4 |
34511132 | Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study. | 2021 Sep 13 |
1 |
| 5 |
34638496 | Aberrant Expression of and Cell Death Induction by Engagement of the MHC-II Chaperone CD74 in Anaplastic Large Cell Lymphoma (ALCL). | 2021 Oct 7 |
1 |
| 6 |
32168429 | Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants. | 2020 May |
2 |
| 7 |
32208297 | A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab. | 2020 May |
1 |
| 8 |
33204104 | A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma. | 2020 |
3 |
| 9 |
31027745 | Next-Generation Sequencer Analysis of Pulmonary Pleomorphic Carcinoma With a CD74-ROS1 Fusion Successfully Treated With Crizotinib. | 2019 May |
1 |
| 10 |
29343973 | A patient with classic biphasic pulmonary blastoma harboring CD74-ROS1 fusion responds to crizotinib. | 2018 |
2 |
| 11 |
29477381 | CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib. | 2018 May 28 |
3 |
| 12 |
29704675 | Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer. | 2018 Jul |
1 |
| 13 |
26673800 | A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. | 2016 May 15 |
3 |
| 14 |
25688157 | Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. | 2015 May 15 |
1 |
| 15 |
23724914 | Acquired resistance to crizotinib from a mutation in CD74-ROS1. | 2013 Jun 20 |
2 |
| 16 |
24047072 | Acquired resistance to crizotinib from a mutation in CD74-ROS1. | 2013 Sep 19 |
1 |
| 17 |
24047073 | Acquired resistance to crizotinib from a mutation in CD74-ROS1. | 2013 Sep 19 |
1 |
| 18 |
22215748 | ROS1 rearrangements define a unique molecular class of lung cancers. | 2012 Mar 10 |
1 |